Design Therapeutics Stock Book Value Per Share
| DSGN Stock | USD 3.70 0.04 1.07% |
Design Therapeutics fundamentals help investors to digest information that contributes to Design Therapeutics' financial success or failures. It also enables traders to predict the movement of Design Stock. The fundamental analysis module provides a way to measure Design Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Design Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0 | 0 | |
| Tangible Book Value Per Share | 0 | 0 |
Design | Book Value Per Share |
Design Therapeutics Company Book Value Per Share Analysis
Design Therapeutics' Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Design Therapeutics Book Value Per Share | 4.92 X |
Most of Design Therapeutics' fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Design Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Design Book Value Per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for Design Therapeutics is extremely important. It helps to project a fair market value of Design Stock properly, considering its historical fundamentals such as Book Value Per Share. Since Design Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Design Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Design Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
| Competition |
Design Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
In accordance with the recently published financial statements, the book value per share of Design Therapeutics is about 4.917 times. This is 389.24% lower than that of the Biotechnology sector and 101.98% lower than that of the Health Care industry. The book value per share for all United States stocks is 99.75% higher than that of the company.
Design Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Design Therapeutics' direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Design Therapeutics could also be used in its relative valuation, which is a method of valuing Design Therapeutics by comparing valuation metrics of similar companies.Design Therapeutics is currently under evaluation in book value per share category among related companies.
Design Fundamentals
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.15 | ||||
| Current Valuation | (56.16 M) | ||||
| Shares Outstanding | 56.49 M | ||||
| Shares Owned By Insiders | 36.66 % | ||||
| Shares Owned By Institutions | 56.82 % | ||||
| Number Of Shares Shorted | 2.23 M | ||||
| Price To Book | 0.75 X | ||||
| Price To Sales | 22,642 X | ||||
| Gross Profit | (48.61 M) | ||||
| EBITDA | (78.19 M) | ||||
| Net Income | (66.86 M) | ||||
| Cash And Equivalents | 359.38 M | ||||
| Cash Per Share | 6.45 X | ||||
| Total Debt | 2.33 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 48.96 X | ||||
| Book Value Per Share | 4.92 X | ||||
| Cash Flow From Operations | (58.56 M) | ||||
| Short Ratio | 7.35 X | ||||
| Earnings Per Share | (1.19) X | ||||
| Target Price | 4.75 | ||||
| Number Of Employees | 58 | ||||
| Beta | 1.83 | ||||
| Market Capitalization | 212.98 M | ||||
| Total Asset | 289.64 M | ||||
| Retained Earnings | (177.63 M) | ||||
| Working Capital | 274.96 M | ||||
| Net Asset | 289.64 M |
About Design Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Design Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Design Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Design Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Design Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Design Therapeutics' short interest history, or implied volatility extrapolated from Design Therapeutics options trading.
Pair Trading with Design Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Design Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Design Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Design Stock
| 0.61 | JNJ | Johnson Johnson Financial Report 18th of July 2024 | PairCorr |
| 0.45 | PFE | Pfizer Inc Report 7th of May 2024 | PairCorr |
The ability to find closely correlated positions to Design Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Design Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Design Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Design Therapeutics to buy it.
The correlation of Design Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Design Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Design Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Design Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Design Therapeutics Piotroski F Score and Design Therapeutics Altman Z Score analysis. To learn how to invest in Design Stock, please use our How to Invest in Design Therapeutics guide.Note that the Design Therapeutics information on this page should be used as a complementary analysis to other Design Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Complementary Tools for Design Stock analysis
When running Design Therapeutics' price analysis, check to measure Design Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Design Therapeutics is operating at the current time. Most of Design Therapeutics' value examination focuses on studying past and present price action to predict the probability of Design Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Design Therapeutics' price. Additionally, you may evaluate how the addition of Design Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Design Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Design Therapeutics. If investors know Design will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Design Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.19) | Revenue Per Share 0.001 | Return On Assets (0.15) | Return On Equity (0.22) |
The market value of Design Therapeutics is measured differently than its book value, which is the value of Design that is recorded on the company's balance sheet. Investors also form their own opinion of Design Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Design Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Design Therapeutics' market value can be influenced by many factors that don't directly affect Design Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Design Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Design Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Design Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.